阿比特龙治疗耐药后将激素从泼尼松更换为地塞米松,可显著降低患者PSA水平。 图1:患者PSA变化曲线(来自邹高德医生真实病例) ■ 病例1提供医生 ■ 病例2提供医生 点评1 点评2 参考文献 [1]Romerolaorden N, Lozano R, Jayaram A, et al. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).[J]. British Journal of Cancer, 2018, 119(9): 1052-1059. [2]Zanardi E, Soldato D, Latocca M M, et al. To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone:[J]. Therapeutic Advances in Urology, 2019. [3]Attard G, Reid A H M, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer[J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2009, 27(23): 3742. [4]Venkitaraman R, Thomas K, Murthy V, et al. A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC [J]. Journal of Clinical Oncology, 2013, 31(6_suppl): 123. [5]Lorente D, Omlin A, Ferraldeschi R, et al. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone[J]. British Journal of Cancer, 2014, 111(12): 2248-2253. [6]Venkitaraman R, Lorente D, Murthy V, et al. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer[J]. European Urology, 2015, 67(4): 673-679.
|
|